623 related articles for article (PubMed ID: 32057187)
41. Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer.
Huang Y; Zhao JJ; Soon YY; Wong A; Aminkeng F; Ang Y; Asokumaran Y; Low JL; Lee M; Choo JRE; Chan G; Kee A; Tay SH; Goh BC; Soo RA
Thorac Cancer; 2022 Nov; 13(22):3152-3161. PubMed ID: 36177913
[TBL] [Abstract][Full Text] [Related]
42. Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial.
Naidoo J; Vansteenkiste JF; Faivre-Finn C; Özgüroğlu M; Murakami S; Hui R; Quantin X; Broadhurst H; Newton M; Thiyagarajah P; Antonia SJ
Lung Cancer; 2022 Apr; 166():84-93. PubMed ID: 35245844
[TBL] [Abstract][Full Text] [Related]
43. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
Criss SD; Mooradian MJ; Sheehan DF; Zubiri L; Lumish MA; Gainor JF; Reynolds KL; Kong CY
JAMA Oncol; 2019 Mar; 5(3):358-365. PubMed ID: 30543349
[TBL] [Abstract][Full Text] [Related]
44. Comparison of seventh TNM and eighth TNM staging system in stage III non-small cell lung cancer patients treated with concurrent chemoradiotherapy.
Yılmaz U; Özdemir Ö; Yılmaz Ü
Curr Probl Cancer; 2019 Feb; 43(1):33-42. PubMed ID: 29804944
[No Abstract] [Full Text] [Related]
45. Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON).
Saito G; Oya Y; Taniguchi Y; Kawachi H; Daichi F; Matsumoto H; Iwasawa S; Suzuki H; Niitsu T; Miyauchi E; Yokoi T; Yokoyama T; Uenami T; Sakata Y; Arai D; Okada A; Nagata K; Teraoka S; Kokubo M
Lung Cancer; 2021 Nov; 161():86-93. PubMed ID: 34543942
[TBL] [Abstract][Full Text] [Related]
46. Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer.
Nishimura A; Ono A; Wakuda K; Kawabata T; Yabe M; Miyawaki T; Miyawaki E; Kodama H; Nishioka N; Mamesaya N; Kobayashi H; Omori S; Kenmotsu H; Naito T; Murakami H; Harada H; Takahashi T
Invest New Drugs; 2022 Apr; 40(2):403-410. PubMed ID: 34633575
[TBL] [Abstract][Full Text] [Related]
47. Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-up.
Parisi E; Genestreti G; Sarnelli A; Ghigi G; Arpa D; Burgio MA; Gavelli G; Rossi A; Scarpi E; Monti M; Tesei A; Polico R; Romeo A
Radiat Oncol; 2019 Jun; 14(1):112. PubMed ID: 31234868
[TBL] [Abstract][Full Text] [Related]
48. Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).
Socinski MA; Özgüroğlu M; Villegas A; Daniel D; Vicente D; Murakami S; Hui R; Gray JE; Park K; Vincent M; Mann H; Newton M; Dennis PA; Antonia SJ
Clin Lung Cancer; 2021 Nov; 22(6):549-561. PubMed ID: 34294595
[TBL] [Abstract][Full Text] [Related]
49. Tumor volume as a potential imaging-based risk-stratification factor in trimodality therapy for locally advanced non-small cell lung cancer.
Kozak MM; Murphy JD; Schipper ML; Donington JS; Zhou L; Whyte RI; Shrager JB; Hoang CD; Bazan J; Maxim PG; Graves EE; Diehn M; Hara WY; Quon A; Le QT; Wakelee HA; Loo BW
J Thorac Oncol; 2011 May; 6(5):920-6. PubMed ID: 21774104
[TBL] [Abstract][Full Text] [Related]
50. Outcome and toxicity of intensity modulated radiotherapy with simultaneous integrated boost in locally advanced non-small cell lung cancer patients.
Fondevilla Soler A; López-Guerra JL; Dzugashvili M; Sempere Rincón P; Sautbaet A; Castañeda P; Díaz JM; Praena-Fernandez JM; Rivin Del Campo E; Azinovic I
Clin Transl Oncol; 2017 Dec; 19(12):1469-1477. PubMed ID: 28589434
[TBL] [Abstract][Full Text] [Related]
51. Pneumonitis Risk After Chemoradiotherapy With and Without Immunotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Han C; Qiu J; Bai L; Liu T; Chen J; Wang H; Dang J
Int J Radiat Oncol Biol Phys; 2024 Jul; 119(4):1179-1207. PubMed ID: 38360117
[TBL] [Abstract][Full Text] [Related]
52. Outcomes of Elderly Patients Who Receive Combined Modality Therapy for Locally Advanced Non-Small-Cell Lung Cancer.
Zaki M; Dominello M; Dyson G; Gadgeel S; Wozniak A; Miller S; Paximadis P
Clin Lung Cancer; 2017 Jan; 18(1):e21-e26. PubMed ID: 27567356
[TBL] [Abstract][Full Text] [Related]
53. Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small-cell lung cancer? A pooled analysis of the literature.
Tsujino K; Kurata T; Yamamoto S; Kawaguchi T; Kubo A; Isa S; Hasegawa Y; Ou SH; Takada M; Ando M
J Thorac Oncol; 2013 Sep; 8(9):1181-9. PubMed ID: 23883782
[TBL] [Abstract][Full Text] [Related]
54. Matched-Pair Analysis of High Dose Versus Standard Dose Definitive Chemoradiation for Locally Advanced Non-Small-Cell Lung Cancer.
Johnson MD; Sura K; Mangona VS; Glick A; Wallace M; Ye H; Grills IS
Clin Lung Cancer; 2017 Mar; 18(2):149-155. PubMed ID: 27426973
[TBL] [Abstract][Full Text] [Related]
55. Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer.
Shirasawa M; Yoshida T; Imabayashi T; Okuma K; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Tsuchida T; Yamamoto N; Nakayama Y; Watanabe SI; Motoi N; Ohe Y
Eur J Cancer; 2022 Feb; 162():1-10. PubMed ID: 34936940
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non-small cell lung cancer: Chinese multicenter report and literature review.
Zhang T; Xu K; Bi N; Zhang L; Jiang W; Liang J; Deng L; Wang X; Wang J; Wang J; Wang L
Thorac Cancer; 2020 Oct; 11(10):2916-2923. PubMed ID: 32833338
[TBL] [Abstract][Full Text] [Related]
57. Complete response induced by anti-PD-1-based immunotherapy with toripalimab in a patient with locally advanced lung adenocarcinoma who failed rapidly after concurrent chemoradiotherapy: A case report.
Xue W; Zhang T; Wang X; Duan J; Bi N
J Clin Pharm Ther; 2020 Dec; 45(6):1511-1514. PubMed ID: 32893899
[TBL] [Abstract][Full Text] [Related]
58. Assessment of chemotherapy regimens on radiation pneumonitis in patients with unresectable stage III non-small-cell lung cancer after definitive chemoradiotherapy.
Sakaguchi T; Ito K; Furuya N; Morikawa K; Fujiwara K; Nishii Y; Inoue T; Hataji O; Mineshita M
Thorac Cancer; 2021 Jul; 12(13):2024-2030. PubMed ID: 34002492
[TBL] [Abstract][Full Text] [Related]
59. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
[TBL] [Abstract][Full Text] [Related]
60. Prognostic Factor and Clinical Outcome in Stage III Non-Small Cell Lung Cancer: A Study Based on Real-World Clinical Data in the Korean Population.
Kim HC; Ji W; Lee JC; Kim HR; Song SY; Choi CM; ;
Cancer Res Treat; 2021 Oct; 53(4):1033-1041. PubMed ID: 33592139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
